Mostrando 5,921 - 5,940 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.67s Limitar resultados
  1. 5921
    por Barroso-Sousa, Romualdo, Tarantino, Paolo, Tayob, Nabihah, Dang, Chau, Yardley, Denise A., Isakoff, Steven J., Valero, Vicente, Faggen, Meredith, Mulvey, Therese, Bose, Ron, Hu, Jiani, Weckstein, Douglas, Wolff, Antonio C., Reeder-Hayes, Katherine, Rugo, Hope S., Ramaswamy, Bhuvaneswari, Zuckerman, Dan, Hart, Lowell, Gadi, Vijayakrishna K., Constantine, Michael, Cheng, Kit, Briccetti, Frederick, Schneider, Bryan, Garrett, Audrey Merrill, Marcom, Kelly, Albain, Kathy, DeFusco, Patricia, Tung, Nadine, Ardman, Blair, Nanda, Rita, Jankowitz, Rachel C., Rimawi, Mothaffar, Abramson, Vandana, Pohlmann, Paula R., Van Poznak, Catherine, Forero-Torres, Andres, Liu, Minetta, Ruddy, Kathryn J., Zheng, Yue, Rosenberg, Shoshana M., Gelber, Richard D., Trippa, Lorenzo, Barry, William, DeMeo, Michelle, Burstein, Harold, Partridge, Ann, Winer, Eric P., Krop, Ian, Tolaney, Sara M.
    Publicado 2022
    “…The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with stage I HER2-positive breast cancer. Moreover, T-DM1 is an established adjuvant treatment for patients with HER2-positive breast cancer with the residual invasive disease after neoadjuvant therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  2. 5922
    “…METHODS: Fifty patients with HER-2 positive breast cancer who planned to receive trastuzumab and pertuzumab therapy for more than four cycles were enrolled in this study, and blood samples were collected. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 5923
  4. 5924
  5. 5925
    “…The Oncotype Dx Breast Recurrence Score® assay has been validated in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) invasive breast cancer (IBC) to predict chemotherapy benefit and distant recurrence risk, regardless of nodal status. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  6. 5926
    “…PURPOSE: To assess whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea in patients with HER2-positive, any-stage breast cancer receiving trastuzumab (H), pertuzumab (P), and a taxane (T; docetaxel or paclitaxel), with/without carboplatin (C; always combined with docetaxel rather than paclitaxel). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 5927
  8. 5928
  9. 5929
    “…BACKGROUND: Pertuzumab plus trastuzumab combined with chemotherapy has become a standard neoadjuvant therapy option for patients with high-risk human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). There is still not enough evidence for the efficacy and safety of neoadjuvant pertuzumab and trastuzumab plus chemotherapy in HER2-positive BC patients in China, both in clinical trials and real-world settings. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 5930
  11. 5931
  12. 5932
  13. 5933
  14. 5934
  15. 5935
  16. 5936
  17. 5937
  18. 5938
  19. 5939
  20. 5940
Herramientas de búsqueda: RSS